
Johnson & Johnson JNJ
€ 245.84
0.89%
Johnson & Johnson Kurzfristige Verbindlichkeiten | JNJ
Kurzfristige Verbindlichkeiten Jährlich Johnson & Johnson
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.1 B | 50.3 B | 46.3 B | 45.2 B | 42.5 B | - | 36 B | 31.2 B | 30.5 B | 27.7 B | - | 25.1 B | 25.7 B | 24.3 B | 23.1 B | 21.7 B | - | 20.9 B | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 54.1 B | 20.9 B | 33.6 B |
Kurzfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Repare Therapeutics
RPTX
|
25.3 M | - | - | $ 112 M | ||
|
Sesen Bio
SESN
|
16.1 M | - | 7.29 % | $ 127 M | ||
|
Windtree Therapeutics
WINT
|
5.72 M | - | - | $ 26.8 M | ||
|
SQZ Biotechnologies Company
SQZ
|
21.8 M | - | 57.95 % | $ 12.8 M | ||
|
MEI Pharma
MEIP
|
1.07 M | - | 10.43 % | $ 20.5 M | ||
|
Palatin Technologies
PTN
|
1.77 M | - | - | $ 13 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Lyra Therapeutics
LYRA
|
9.52 M | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
1.66 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
27.3 M | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
3.3 M | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
35.1 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
4.79 M | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
87.1 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
48.4 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
42.6 M | $ 4.21 | 4.99 % | $ 653 M | ||
|
AbbVie
ABBV
|
43.3 B | $ 291.22 | 1.06 % | $ 515 B | ||
|
22nd Century Group
XXII
|
7.27 M | $ 1.56 | -19.17 % | $ 287 K | ||
|
Axon Enterprise
AXON
|
1.47 B | $ 313.68 | -18.01 % | $ 24.5 B | ||
|
Biogen
BIIB
|
3.35 B | $ 248.51 | 1.88 % | $ 36.4 B | ||
|
Exelixis
EXEL
|
406 M | $ 69.55 | 1.22 % | $ 18.9 B | ||
|
Geron Corporation
GERN
|
112 M | $ 0.99 | 3.97 % | $ 660 M | ||
|
Gilead Sciences
GILD
|
11.8 B | $ 166.9 | -0.4 % | $ 208 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
1.47 B | $ 155.97 | -0.44 % | $ 20.4 B | ||
|
INmune Bio
INMB
|
8.42 M | $ 1.12 | -4.68 % | $ 27.7 M | ||
|
Insmed Incorporated
INSM
|
469 M | $ 114.55 | 5.32 % | $ 22.8 B | ||
|
Titan Pharmaceuticals
TTNP
|
483 K | - | -3.76 % | $ 3.47 M | ||
|
Lineage Cell Therapeutics
LCTX
|
11.4 M | $ 1.02 | 3.75 % | $ 235 M | ||
|
BioVie
BIVI
|
2.27 M | $ 1.33 | 9.92 % | $ 1.96 M | ||
|
Longeveron
LGVN
|
4.09 M | $ 1.82 | 6.43 % | $ 32 B | ||
|
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | ||
|
TCR2 Therapeutics
TCRR
|
64.1 M | - | - | $ 58.1 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
85.1 M | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
Mustang Bio
MBIO
|
7.91 M | $ 0.39 | 0.15 % | $ 1.91 M | ||
|
TFF Pharmaceuticals
TFFP
|
2.43 M | - | -60.05 % | $ 125 K | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 1.63 | 1.87 % | $ 2.68 M | ||
|
Mirum Pharmaceuticals
MIRM
|
206 M | $ 93.81 | 0.28 % | $ 4.71 B | ||
|
Adaptimmune Therapeutics plc
ADAP
|
64.5 M | - | -15.15 % | $ 60.3 M | ||
|
AVEO Pharmaceuticals
AVEO
|
18.7 M | - | - | $ 521 M | ||
|
Codexis
CDXS
|
25.3 M | $ 1.09 | 6.37 % | $ 95 M |